Navigation Links
PSA Testing Linked to Improved Prostate Cancer Survival
Date:8/23/2012

THURSDAY, Aug. 23 (HealthDay News) -- Prostate cancer survival rates in the United States have improved since the introduction of prostate-specific antigen (PSA) testing, researchers report.

PSA is a protein released into the body by the prostate gland. PSA screening involves measuring the amount of PSA in a man's blood. The higher the PSA level, the more likely it is that a man has prostate cancer.

The new study, published Aug. 23 in The Journal of Urology, found that routine use of PSA testing for prostate cancer screening and monitoring has resulted in earlier and more sensitive detection of the disease. This has led to improved survival for patients with newly diagnosed prostate cancer that has spread to the bones or other parts of the body ("metastatic prostate cancer").

In addition, the survival rate for black patients has improved and is now about the same as for whites, the investigators found.

For the study, researchers analyzed data from three clinical trials conducted over the last three decades that evaluated patient survival after androgen (hormone)-deprivation treatment for prostate cancer. Two of the clinical trials were conducted before the introduction of PSA screening, and one took place after.

Median survival was 30 months in the first trial (conducted from 1985 to 1986), 33 months in the second trial (conducted from 1989 to 1994), and 49 months in the third trial (conducted from 1995 to 2009). Patients in the most recent trial also had a 30 percent decreased risk of death, the study found.

Among black patients, median survival was 27 months in the first trial and 48 months in the third trial, which is close to that of white patients, the study authors noted in a journal news release.

This improvement in black patients' survival may be due to greater awareness of prostate cancer and increased likelihood that they will seek health care, suggested lead investigator Dr. Ian Thompson, director of the Cancer Therapy and Research Center, a U.S. National Cancer Institute-designated cancer center, and a professor in the urology department at the University of Texas Health Science Center at San Antonio.

However, Thompson noted that black men have a twofold to threefold greater incidence of newly diagnosed metastatic prostate cancer than white men, which contributes to a similarly higher death rate. This shows the need for a greater effort to eliminate disparities in prostate cancer, he pointed out in the news release.

While not all of the improvements in prostate cancer survival "can be attributed strictly to PSA testing, without a doubt it has played a role in extending many lives," Thompson concluded.

PSA testing has been controversial.

In May, the U.S. Preventive Services Task Force recommended against routine PSA screening, saying too many non-dangerous cancers were being treated aggressively and resulting in unnecessary harm.

But a July study in the journal Cancer found that not screening American men would triple the number developing advanced cancer, and the American Society of Clinical Oncology recommended that men with a life expectancy of more than 10 years talk with their doctors about getting the test.

While the new study uncovered an association between routine PSA testing and improved rates of prostate cancer survival, it did not prove a cause-and-effect relationship.

More information

The U.S. National Cancer Institute has more about PSA testing.

-- Robert Preidt

SOURCE: The Journal of Urology, news release, Aug. 23, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Sensor detects glucose in saliva and tears for diabetes testing
2. Prostate cancer survival rates improved since introduction of PSA testing
3. HIV home testing kits prove their worth
4. By studying animal health, researchers find improved ways for developing, testing cancer therapies
5. Heterogeneous ER+ breast cancer models allow more accurate drug testing
6. What would happen without PSA testing?
7. HPV testing in HIV-positive women may help reduce frequent cervical cancer screening
8. Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer
9. Wednesday Is National HIV Testing Day
10. Experts recommend men at risk for osteoporosis undergo bone density testing
11. Guidelines Issued for When Docs Should Order Vascular Testing
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
PSA Testing Linked to Improved Prostate Cancer Survival
(Date:4/24/2017)... ... April 24, 2017 , ... ... seeking public support to bring their novel lifesaving device for the everyday use ... with medical-grade sensors, specially designed to read a child’s vital signs, and detect ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... are expected to be diagnosed globally; approximately 25,000 of them will be malignant.(1) ... greater use of this type of healthcare model in the diagnosis and treatment ...
(Date:4/24/2017)... ... April 24, 2017 , ... Come to PAINWeekEnd (PWE) Tampa on May 20 ... an educational and exciting 2-day program. , An attendee at a recent PAINWeekEnd ... approach patients” about the course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Learning to Use Your SPIRITUAL COMPASS To Navigate ... Use Your SPIRITUAL COMPASS To Navigate Life Issues” is the creation of published author, ... the Board of Directors for CONTACT USA, and former member of the American Association ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... the development of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic ... manufacture its ANCD BRAIN device as the product advances towards regulatory and clinical ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/18/2017)... April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and providing ... is in conjunction with this morning,s announcement of the ... and Nutritional Insufficiency businesses. Cardinal Health now ... will be at the bottom of its previous guidance ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, 2017 ... ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and Cameron ... announced the signing of a three-year exclusive sales ... deploy a dedicated sales team to introduce Imprimis, ... primarily focused in 13 states in the U.S. ...
Breaking Medicine Technology: